Investigational drug · Phase 2
LUM015
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "LUM015"
First trial start
2016
Aug 4, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LUM015", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Pancreatic Cancer
- Esophageal Cancer
- Gastric Cancer
Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "LUM015" as an intervention, largest first.
- Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer PatientsTerminated
Lumicell, Inc.Industry
NCT04440982 · 98 participants · Start Sep 1, 2020 · Primary completion Nov 30, 2023
Drug: LUM015 · For: Breast Cancer; Neoadjuvant Therapy
Sites: Palo Alto, California; Clearwater, Florida; Boston, Massachusetts · 6 sites in all
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersActive, not recruiting
Lumicell, Inc.Industry
NCT02584244 · 66 participants (planned) · Start Aug 4, 2016 · Primary completion Feb 2027
Drug: LUM015 · For: Colorectal Cancer; Pancreatic Cancer; Esophageal Cancer and 1 more
Sites: Boston, Massachusetts
Lumicell, Inc.Industry
NCT02438358 · 60 participants · Start Jun 2015 · Primary completion Sep 2017
Drug: LUM015 · For: Breast Cancer
Sites: Boston, Massachusetts
David KirschAcademic, hospital or other
NCT01626066 · 15 participants · Start Jun 2012 · Primary completion Aug 2014
Drug: LUM015 · For: Sarcoma; Soft Tissue Sarcoma; Breast Cancer
Sites: Durham, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
- Near-Infrared Fluorescence Probes for Fluorescence-Guided Surgery: Current Clinical Probes and Emerging Candidates.
Kang Z, Jiang X, Jin G, et al. · Molecules 2026
- Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review.
Hennessy M, Neville JJ, Privitera L, et al. · Children (Basel) 2025
- Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery.
Lanahan CR, Kelly BN, Gadd MA, et al. · Breast Cancer Res Treat 2021
- Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery.
Smith BL, Lanahan CR, Specht MC, et al. · Ann Surg Oncol 2020
- Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer.
Esfahani SA, Heidari P, Kucherlapati MH, et al. · Am J Nucl Med Mol Imaging 2019
- Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
Smith BL, Gadd MA, Lanahan CR, et al. · Breast Cancer Res Treat 2018
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.